We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Cardiovascular Benefit of CPAP May Be Greater in High-Risk Obstructive Sleep Apnoea

MedXY Editorial Team•May 15, 2026•Cardiology
cardiovascular outcomesCPAPhypoxic burdenobstructive sleep apnoeaprecision medicine

Background

Obstructive sleep apnoea (OSA) is a common sleep disorder in which the upper airway repeatedly collapses during sleep, causing breathing pauses, fragmented sleep, and drops in blood oxygen levels. These repeated events place strain on the heart and blood vessels. OSA is strongly linked with hypertension, coronary artery disease, stroke, heart failure, and other cardiovascular problems.

Continuous positive airway pressure, or CPAP, is the standard treatment for moderate to severe OSA. It works by delivering a steady stream of air through a mask to keep the airway open during sleep. CPAP improves breathing and sleep quality, but large randomized trials in patients with cardiovascular disease have generally not shown a clear reduction in major cardiovascular events overall. That has raised an important question: could CPAP help some patients more than others?

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare DataAmong older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitoriSep 19, 2026Intracoronary Imaging-Guided PCI: Updated Meta-Analysis Validates Cardiovascular Outcome BenefitsThis updated meta-analysis of 28 RCTs reveals significant reductions in cardiovascular events and mortality with intracoronary imaging-guided PCI versus angiography-guided PCI, highlighting the importance of lesion and geographic factors inSep 19, 2026Impact of Digitalis Glycosides on Cardiovascular Outcomes in HFmrEF and HFrEF: A Comprehensive Evidence SynthesisDigitalis glycosides reduce cardiovascular death or worsening heart failure events in HFmrEF and HFrEF patients over a median of 36–37 months, supported by randomized trials and meta-analyses highlighting their role in select heart failureSep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis: A Precision Medicine Imperative
Clonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical com
Sep 15, 2026
Rapid Immunoassay for Molecular Subphenotyping in Pediatric Acute Cardiorespiratory Failure: Clinical Implications and Future DirectionsRapid immunoassay-based classifiers accurately identify hyper- and hypoinflammatory subphenotypes in critically ill children, preserving prognostic and predictive utility and enabling precision therapies in acute pediatric cardiorespiratorySep 13, 2026
Advancing Prognostic Precision in HFpEF: The LIFE-Preserved Risk Prediction ModelThe LIFE-Preserved model accurately predicts short-term and lifetime risks of heart failure hospitalization or cardiovascular death in HFpEF patients, enabling tailored clinical risk stratification and improved management.Sep 11, 2026